Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
PfizerPFE |
$13M |
 |
AstrazenecaAZN |
-$480,000 |
 |
Johnson & JohnsonJNJ |
-$631M |
 |
ModernaMRNA |
-$1.8B |
 |
AbbVieABBV |
-$378M |
Are Mira Pharmaceuticals Insiders Buying or Selling?
Mira Pharmaceuticals (MIRA) has had no reported insider transactions in the past 90 days. The most recent was Erez Aminov, who sold 613,595 shares at $2.11 on October 16, 2025.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the MIRA AI Score. For government officials trading this stock, see MIRA congressional trading.
Who’s Trading Mira Pharmaceuticals Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| Erez Aminov | Sold $1.4M | 3 | Oct 16, 2025 |
Recent Mira Pharmaceuticals Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Erez Aminov | Oct 16, 2025 | Sell | 613,595 | $2.11 | $1.3M |
| Erez Aminov | Nov 20, 2024 | Sell | 44,590 | $1.27 | $57,000 |
| Erez Aminov | Nov 19, 2024 | Sell | 55,410 | $1.39 | $77,000 |
Frequently Asked Questions: Mira Pharmaceuticals Insider Trading
Mira Pharmaceuticals insiders have not reported any transactions in the past 90 days.
The most recent sale was by Erez Aminov who sold 613,595 shares on October 16, 2025. View all transactions in the table on this page.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Aminov Erez has sold the most MIRA stock in the last 2 years, with a total value of $1.4M.
The total value of insider transactions for Mira Pharmaceuticals in the last 2 years is negative, amounting to -$1.4M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
